Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: J Allergy Clin Immunol. 2021 May 15;149(1):379–387. doi: 10.1016/j.jaci.2021.04.034

Figure 3. Plasma ADA2 activity in carriers of ADA2 variants.

Figure 3.

A) Comparison of plasma ADA2 activity levels in patients with DADA2 (n = 6), carriers of predicted pLoF variants (n = 9), carriers of missense variants (n = 36) and age-matched healthy controls (HC; n = 50). B) Correlation between plasma ADA2 activity in carriers (n = 45) and residual enzymatic activity of specific variants determined by in vitro studies. Individual variant and label are color coded. Dotted lines indicate reference range for healthy controls and patients with DADA2. Upper and lower limit of healthy controls were defined as the 98th and 2nd percentile, respectively.